Guest columnist: Washington should ensure stable hemp market | State-Journal
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Cannabinoid-Based Therapies Linked to Reduced Agitation in Alzheimer’s Patients, Meta …
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
Michigan universities can’t study dispensary pot on campus. MSU went mobile
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
DEA Judge Issues Procedural Order for Marijuana Rescheduling Hearing
The DEA marijuana rescheduling procedural order sets the framework for the upcoming hearing on moving cannabis to Schedule III. This order establishes evidentiary standards that will influence federal cannabis research and clinical use. Clinicians should…
PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder
/* Suppress TOC widgets */ #ez-toc-container, .ez-toc-wrap, .ez-toc-v2_0, div.ez-toc-v2_0, div#ez-toc-container { display: none !important; visibility: hidden !important; height: 0 !important; opacity: 0 !important; } /* Constrain oversized headline…
DEA Schedule I Synthetic Cannabinoids Control Update June 2026
This update covers the DEA Schedule I synthetic cannabinoids control update as of June 19, 2026. It details regulatory actions impacting synthetic cannabinoids and related substances. The report informs clinical practice and legal considerations.
Schedules of Controlled Substances: Rescheduling FDA-Approved Cannabis Products and Permit Changes
The rescheduling FDA approved cannabis products implications are significant for clinical research and prescribing. This regulatory update moves certain cannabis-derived medications to Schedule III, easing permit requirements. Clinicians should…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA has placed several synthetic cannabinoids into Schedule I, highlighting their high abuse potential and lack of accepted medical use. This synthetic cannabinoids schedule I classification includes 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has enacted synthetic ketamine analog regulation by temporarily placing 2-fluorodeschloroketamine in Schedule I. This action highlights the challenges of controlling emerging designer drugs. Clinicians should monitor these regulatory changes…
DEA Updates Synthetic Dissociative Scheduling: Diphenidine in Schedule I
The DEA synthetic dissociative scheduling update places diphenidine in Schedule I due to its high abuse potential and lack of accepted medical use. This reflects regulatory efforts to control emerging novel psychoactive substances. Clinicians should…
